Categories: Stock Market

UnitedHealth’s lower-than-feared costs lift profit, shares By Reuters


© Reuters. The corporate logo of the UnitedHealth Group appears on the side of one of their office buildings in Santa Ana, California, U.S., April 13, 2020. REUTERS/Mike Blake

(Reuters) -UnitedHealth Group’s quarterly profit beat Wall Street estimates on Friday as a smaller-than-expected jump in medical costs allayed fears that a resumption in long-delayed surgical procedures would hit profit growth, sending its shares up 4%.

The results also lifted the shares of rivals Humana (NYSE:), Cigna (NYSE:) and CVS Health (NYSE:) between 2% and 2.5% in premarket trading.

Shares across the sector slumped last month after UnitedHealth (NYSE:) said it was recording higher payouts over medical care between April and early June, as older adults became more comfortable visiting doctors’ offices again as COVID risks receded.

The beat provides a “welcomed respite today” after several weeks of pain for investors in health insurance companies, Stephens analyst Scott Fidel said in a note.

UnitedHealth’s medical loss ratio for the quarter – the percentage of spend on claims compared to premiums collected – was 83.2%, compared to analysts’ expectations of 83.4%.

Health insurers’ medical costs were suppressed during pandemic-led lockdowns as people delayed non-urgent surgeries such as hip and knee replacements.

Older adults are usually covered by government-backed Medicare insurance plans, which insurers such as UnitedHealth and Humana offer.

UnitedHealth raised the lower end of its annual adjusted profit forecast to $24.70, from $24.50 per share previously, while keeping the top end unchanged at $25 per share.

Humana also warned of a jump in its medical costs for this year in June after noting similar concerns as UnitedHealth. The two companies are the biggest providers of Medicare Advantage plans for older adults.

UnitedHealth posted an adjusted profit of $6.14 per share for the second quarter ended June 30, above analysts’ expectations of $5.99, according to Refinitiv IBES data.

Source link

nasdaqpicks.com

Share
Published by
nasdaqpicks.com

Recent Posts

Churchill in Moscow review — Roger Allam stars in a timely reflection on realpolitik

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories…

7 minutes ago

Choke Enough album review — hyperpop gets the grown-up treatment

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories…

23 minutes ago

Why Argentina is back in love with the peso — for now

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories…

40 minutes ago

Illinois politician Mike Madigan found guilty of bribery and wire fraud

Unlock the White House Watch newsletter for freeYour guide to what the 2024 US election…

55 minutes ago

Semiconductor equipment manufacturing firm Lam Research to invest ₹10,000 crore in Karnataka

Global semiconductor equipment manufacturing firm Lam Research has committed an investment of over ₹10,000 crore…

56 minutes ago

Kauvery Hospitals’ investment arm invests in start-up Lifesigns

Healthcare Capital, the investment arm of the Kauvery Hospital Group, has invested an undisclosed amount…

1 hour ago